Strides Arcolab is currently trading at Rs. 754.55, up by 2.25 points or 0.30% from its previous closing of Rs. 752.30 on the BSE.
The scrip opened at Rs. 751.90 and has touched a high and low of Rs. 768.00 and Rs. 747.00 respectively. So far 38650 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 794.00 on 18-Jul-2012 and a 52 week low of Rs. 276.25 on 22-Aug-2011.
Last one week high and low of the scrip stood at Rs. 794.00 and Rs. 735.00 respectively. The current market cap of the company is Rs. 4408.10 crore.
The promoters holding in the company stood at 28.27% while Institutions and Non-Institutions held 54.03% and 17.70% respectively.
French Development Financing Institution, Proparco has invested $12.5 million for 20% stake in Strides Arcolabs’ African front end arm, valuing the African operations at about $60 million. The funds raised will be used to create additional manufacturing infrastructure in key markets in Africa and to build a regional company with the philosophy of 'In Africa for Africa.’
Strides Africa has strategically organized its front end African business into a Strategic Business Unit. The business operates in the branded generics and OTC generics segments and has footprints in 23 Sub Saharan African countries, excluding South Africa. The company has been present in Africa and contributing to the improvement of healthcare by manufacturing and marketing a wide range of lifesaving antibiotics etc.
Strides Arcolab is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures wide range of IP-lead niche pharmaceutical products with an emphasis on sterile injectables
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: